Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine

Transplant International

Volumn 21, Issue 3, 2008, Pages 223-233

  Hecking, Manfred ^a   Kainz, Alexander ^a   Schillinger, Martin ^a   Posch, Christian ^a   Birsan, Tudor ^a   Rasoul Rockenschaub, Susanne ^a   Böhmig, Georg A ^a   Schmaldienst, Sabine ^a   Watschinger, Bruno ^a   Hörl, Walter H ^a   Mühlbacher, Ferdinand ^a   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C2 monitoring; Cyclosporine; Hepatic function; Renal transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN A; GLUCOCORTICOID; LACTATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALOACETIC ACID; RAPAMYCIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG FORMULATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; PATIENT MONITORING; PRIORITY JOURNAL; RECIPIENT;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CYCLOSPORINE; DRUG MONITORING; EMULSIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; L-LACTATE DEHYDROGENASE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 38849147666     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00563.x     Document Type: Article

References (41)

1. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002 2 : 148.
2. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002 2 : 157.
3. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 2002 24 : 40.
4. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001 15 : 279.
5. Nashan B, Bock A, Bosmans JL, et al. Use of Neoral C monitoring: a European consensus. Transpl Int 2005 18 : 768.
6. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003 76 : 903.
7. Fritsche L, Dragun D, Neumayer HH, Budde K. Impact of cyclosporine on the development of immunosuppressive therapy. Transplant Proc 2004 36 : 130S.
8. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 2004 36 : 420S.
9. Citterio F, Scata MC, Romagnoli J, Nanni G, Castagneto M. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion. Transplantation 2005 79 : 802.
10. Kowdley KV, Keeffe EB. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am 1995 24 : 991.
11. Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog Histochem Cytochem 2004 39 : 85.
12. Lorber MI, Van Buren CT, Flechner SM, Williams C, Kahan BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 1987 43 : 35.
13. Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, Van Buren CT. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 1987 43 : 197.
14. Cadranel JF, Erlinger S, Desruenne M, et al. Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man. Dig Dis Sci 1992 37 : 1473.
15. Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. Liver injury from cyclosporine A. Dig Dis Sci 1990 35 : 693.
16. Birsan T, Loinig C, Bodingbauer M, et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Transplantation 2004 78 : 1787.
17. Videla C, Vega J, Borja H. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole. Transplant Proc 2005 37 : 1574.
18. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002 73 : 953.
19. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990 11 : 272.
20. Kadmon M, Klunemann C, Bohme M, et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 1993 104 : 1507.
21. Bohme M, Jedlitschky G, Leier I, Buchler M, Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enzyme Regul 1994 34 : 371.
22. Bohme M, Muller M, Leier I, Jedlitschky G, Keppler D. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 1994 107 : 255.
23. Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin Liver Dis 2000 20 : 273.
24. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000 118 : 422.
25. Adachi Y, Kamisako T. Intrahepatic cholestasis. Nippon Rinsho 1996 54 : 788.
26. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002 123 : 1649.
27. Christians U, Kohlhaw K, Surig T, et al. Parallel blood concentrations of second-generation cyclosporine metabolites and bilirubin in liver graft recipients. Ther Drug Monit 1995 17 : 487.
28. Elamiri A, Perwaiz S, Tuchweber B, Yousef IM. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol Res 2003 48 : 467.
29. Azer SA, Stacey NH. Differential effects of cyclosporin A on the transport of bile acids by human hepatocytes. Biochem Pharmacol 1993 46 : 813.
30. Galan AI, Zapata AJ, Roman ID, et al. Impairment of maximal bilirubin secretion by cyclosporin A in the rat. Arch Int Physiol Biochim Biophys 1991 99 : 373.
31. Roman ID, Fernandez-Moreno MD, Fueyo JA, Roma MG, Coleman R. Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol Sci 2003 71 : 276.
32. Jansen PL, Muller M, Kuipers F. Bile formation and cholestasis. Ned Tijdschr Geneeskd 2000 144 : 2384.
33. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J Pediatr Gastroenterol Nutr 2005 41 : 235.
34. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002 73 : 775.
35. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002 359 : 741.
36. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999 67 : 1036.
37. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000 69 : 1252.
38. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002 74 : 1070.
39. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006 81 : 1234.
40. Albano L, Casez JP, Bekri S, et al. Effects of tacrolimus vs cyclosporin-A on bone metabolism after kidney transplantation: a cross-sectional study in 28 patients. Nephrol Ther 2005 1 : 115.
41. Einecke G, Schutz M, Mai I, et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005 20 : 1463.